Skip to main content
Top

08-06-2024 | Urothelial Cancer | Research

Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project

Authors: Alessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, Samer Salah, Javier Molina-Cerrillo, Francesco Massari, Ray Manneh Kopp, Ondřej Fiala, Luca Galli, Zin W. Myint, Deniz Tural, Andrey Soares, Renate Pichler, Alessia Mennitto, Halima Abahssain, Fabio Calabrò, Fernando Sabino M. Monteiro, Anna Albano, Veronica Mollica, Giulia Claire Giudice, Hideki Takeshita, Matteo Santoni, ARON Working Group

Published in: Clinical & Experimental Metastasis

Login to get access

Abstract

Upper tract urothelial carcinoma (UTUC) accounts for the 5–10% of all urothelial carcinomas (UCs). In this analysis, we reported the real-world data from the ARON-2 study (NCT05290038) on the efficacy of pembrolizumab in patients with UTUC who recurred or progressed after platinum-based chemotherapy. Medical records of patients with metastatic UTUC treated with pembrolizumab as second-line therapy were reviewed from 34 institutions in 14 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate (ORR). Univariate and multivariate analyses were used to explore the association of variables of interest with OS and PFS. 235 patients were included in our analysis. Median OS was 8.6 months (95% CI 6.6–12.1), the 1 year OS rate was 43% while the 2 years OS rate 29%. The median PFS was 5.1 months (95% CI 3.9–6.9); 46% of patients were alive at 6 months, 34% at 12 months and 25% at 24 months. According to RECIST 1.1, 18 patients (8%) experienced complete response (CR), 57 (24%) partial response (PR), 44 (19%) stable disease (SD), and 116 (49%) progressive disease (PD), with an ORR of 32%. Our study confirms the effectiveness of pembrolizumab in patients pretreated with a platinum-based combination, irrespective of their sensitivity to the first-line treatment and of their histology. In addition, we emphasized the limited benefit of the treatment with pembrolizumab in patients with hepatic metastases and poor ECOG performance status.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mohanty SK, Lobo A, Cheng L (2022) The 2022 revision of World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol S0046–8177(22):00224–00226 Mohanty SK, Lobo A, Cheng L (2022) The 2022 revision of World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol S0046–8177(22):00224–00226
4.
go back to reference Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fernández MI, Kikuchi E, Chade DC, Babjuk M, Grollman AP, Thalmann GN (2017) Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 35(3):379–387. https://doi.org/10.1007/s00345-016-1928-xCrossRefPubMed Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fernández MI, Kikuchi E, Chade DC, Babjuk M, Grollman AP, Thalmann GN (2017) Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 35(3):379–387. https://​doi.​org/​10.​1007/​s00345-016-1928-xCrossRefPubMed
10.
go back to reference Cathomas R, Lorch A, Bruins HM, Compérat EM, Cowan NC, Efstathiou JA, Fietkau R, Gakis G, Hernández V, Espinós EL, Neuzillet Y (2022) The 2021 updated european association of urology guidelines on metastatic urothelial carcinoma. Eur Urol 81(1):95–103CrossRefPubMed Cathomas R, Lorch A, Bruins HM, Compérat EM, Cowan NC, Efstathiou JA, Fietkau R, Gakis G, Hernández V, Espinós EL, Neuzillet Y (2022) The 2021 updated european association of urology guidelines on metastatic urothelial carcinoma. Eur Urol 81(1):95–103CrossRefPubMed
11.
go back to reference Powles T, Smith K, Stenzl A, Bedke J (2017) Immune checkpoint inhibition in metastatic urothelial cancer. Eur Urol 72:477–481CrossRefPubMed Powles T, Smith K, Stenzl A, Bedke J (2017) Immune checkpoint inhibition in metastatic urothelial cancer. Eur Urol 72:477–481CrossRefPubMed
12.
go back to reference Rouprêt M, Seisen T, Birtle AJ, Capoun O, Compérat EM, Dominguez-Escrig JL, Gürses Andersson I, Liedberg F, Mariappan P, Hugh Mostafid A, Pradere B, van Rhijn BWG, Shariat SF, Rai BP, Soria F, Soukup V, Wood RG, Xylinas EN, Masson-Lecomte A, Gontero P (2023) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol S0302–2838(23):02652. https://doi.org/10.1016/j.eururo.2023.03.013CrossRef Rouprêt M, Seisen T, Birtle AJ, Capoun O, Compérat EM, Dominguez-Escrig JL, Gürses Andersson I, Liedberg F, Mariappan P, Hugh Mostafid A, Pradere B, van Rhijn BWG, Shariat SF, Rai BP, Soria F, Soukup V, Wood RG, Xylinas EN, Masson-Lecomte A, Gontero P (2023) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol S0302–2838(23):02652. https://​doi.​org/​10.​1016/​j.​eururo.​2023.​03.​013CrossRef
13.
go back to reference Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF (2017) KEYNOTE-045 investigators pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. https://doi.org/10.1056/NEJMoa1613683CrossRefPubMedPubMedCentral Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF (2017) KEYNOTE-045 investigators pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. https://​doi.​org/​10.​1056/​NEJMoa1613683CrossRefPubMedPubMedCentral
14.
go back to reference Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30(6):970–976. https://doi.org/10.1093/annonc/mdz127CrossRefPubMedPubMedCentral Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30(6):970–976. https://​doi.​org/​10.​1093/​annonc/​mdz127CrossRefPubMedPubMedCentral
16.
go back to reference Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S et al (2016) RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 62:132–7CrossRefPubMedPubMedCentral Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S et al (2016) RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 62:132–7CrossRefPubMedPubMedCentral
18.
19.
go back to reference Rao A, McGrath JE, Xiu J, de Souza AL, Gulati S, Abuali I, Sagaram S, Nabhan C, Korn WM, Ryan CJ et al (2021) Characterization of microsatellite instability (dMMR/MSI-H) and mutational landscape in a large contemporary cohort of upper tract urothelial cancer (UTUC) patients. J Clin Oncol 39:465CrossRef Rao A, McGrath JE, Xiu J, de Souza AL, Gulati S, Abuali I, Sagaram S, Nabhan C, Korn WM, Ryan CJ et al (2021) Characterization of microsatellite instability (dMMR/MSI-H) and mutational landscape in a large contemporary cohort of upper tract urothelial cancer (UTUC) patients. J Clin Oncol 39:465CrossRef
20.
go back to reference Andreev-Drakhlin A, Shah AY, Adriazola AC, Shaw L, Lopez L, James M, Matin SF, Alhalabi O, Gao J, Siefker-Radtke AO et al (2021) Efficacy of immune checkpoint blockade in patients with advanced upper tract urothelial cancer and mismatch repair deficiency or microsatellite instability (MSI). J Clin Oncol 39:487CrossRef Andreev-Drakhlin A, Shah AY, Adriazola AC, Shaw L, Lopez L, James M, Matin SF, Alhalabi O, Gao J, Siefker-Radtke AO et al (2021) Efficacy of immune checkpoint blockade in patients with advanced upper tract urothelial cancer and mismatch repair deficiency or microsatellite instability (MSI). J Clin Oncol 39:487CrossRef
21.
go back to reference O’Donnell PH, Balar AV, Castellano DE, De Wit R, Vaughn DJ, Powles T, Vuky J, Lee JL, Fradet Y, Bellmunt J, Fong L, Petrylak DP, Gerritsen WR, Quinn DI, Culine S, Bajorin DF, Jin Zhi X, Imai K, Moreno BH, Grivas P (2022) Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials. J Clin Oncol. https://doi.org/10.1200/JCO.2022.40.6_suppl.516CrossRefPubMedPubMedCentral O’Donnell PH, Balar AV, Castellano DE, De Wit R, Vaughn DJ, Powles T, Vuky J, Lee JL, Fradet Y, Bellmunt J, Fong L, Petrylak DP, Gerritsen WR, Quinn DI, Culine S, Bajorin DF, Jin Zhi X, Imai K, Moreno BH, Grivas P (2022) Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials. J Clin Oncol. https://​doi.​org/​10.​1200/​JCO.​2022.​40.​6_​suppl.​516CrossRefPubMedPubMedCentral
22.
go back to reference Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P (2021) Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU Int 128(2):196–205. https://doi.org/10.1111/bju.15324CrossRefPubMed Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P (2021) Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU Int 128(2):196–205. https://​doi.​org/​10.​1111/​bju.​15324CrossRefPubMed
23.
go back to reference Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura Y, Kishitani K, Miyakawa J, Sugimoto K, Nakamura Y, Niimi F, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H (2023) Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab. Immunotherapy. https://doi.org/10.2217/imt-2023-0028CrossRefPubMed Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura Y, Kishitani K, Miyakawa J, Sugimoto K, Nakamura Y, Niimi F, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H (2023) Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab. Immunotherapy. https://​doi.​org/​10.​2217/​imt-2023-0028CrossRefPubMed
24.
go back to reference Bersanelli M, Mazzaschi G, Giannatempo P, Raggi D, Farè E, Maruzzo M, Basso U, De Giorgi U, Vignani F, Banna GL, Stellato M, Tambaro R, Naglieri E, Losanno T, Procopio G, Pignata S, Necchi A, Buti S (2022) Immunotherapy and sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). Immunotherapy 14(2):107–114. https://doi.org/10.2217/imt-2021-0109CrossRefPubMed Bersanelli M, Mazzaschi G, Giannatempo P, Raggi D, Farè E, Maruzzo M, Basso U, De Giorgi U, Vignani F, Banna GL, Stellato M, Tambaro R, Naglieri E, Losanno T, Procopio G, Pignata S, Necchi A, Buti S (2022) Immunotherapy and sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). Immunotherapy 14(2):107–114. https://​doi.​org/​10.​2217/​imt-2021-0109CrossRefPubMed
25.
go back to reference Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390(10):875–88CrossRefPubMed Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390(10):875–88CrossRefPubMed
Metadata
Title
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project
Authors
Alessandro Rizzo
Sebastiano Buti
Patrizia Giannatempo
Samer Salah
Javier Molina-Cerrillo
Francesco Massari
Ray Manneh Kopp
Ondřej Fiala
Luca Galli
Zin W. Myint
Deniz Tural
Andrey Soares
Renate Pichler
Alessia Mennitto
Halima Abahssain
Fabio Calabrò
Fernando Sabino M. Monteiro
Anna Albano
Veronica Mollica
Giulia Claire Giudice
Hideki Takeshita
Matteo Santoni
ARON Working Group
Publication date
08-06-2024
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-024-10296-0
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare